Why is aTyr Pharma stock gaining today?
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
aTyr Pharma Inc (ATYR)
aTyr Pharma Inc stock price live, this page displays NASDAQ ATYR stock exchange data. View the ATYR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the aTyr Pharma Inc real time stock price chart below.
What Is the aTyr Pharma Inc Stock Price Today?
The aTyr Pharma Inc stock price today is 0.559.
What Is the Stock Symbol for aTyr Pharma Inc?
The stock ticker symbol for aTyr Pharma Inc is ATYR.
Is ATYR the Same as $ATYR?
$ATYR is a common way to refer to the aTyr Pharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does aTyr Pharma Inc Trade On?
aTyr Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether aTyr Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current aTyr Pharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATYR quote. (ISIN: US0021202025)
What Is the aTyr Pharma Inc Stock Price Today?
The aTyr Pharma Inc stock price today is 0.559.
What Is the Stock Symbol for aTyr Pharma Inc?
The stock ticker symbol for aTyr Pharma Inc is ATYR.
Is ATYR the Same as $ATYR?
$ATYR is a common way to refer to the aTyr Pharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does aTyr Pharma Inc Trade On?
aTyr Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is aTyr Pharma Inc a Good Stock to Buy?
Determining whether aTyr Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current aTyr Pharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATYR quote. (ISIN: US0021202025)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.550
0.587
52 wk Range
0.395
6.500
Unusual Post-Market activity
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5500.587
52 wk Range
0.3956.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATYR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
2.857
Upside
+411.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Life Tech Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Life Tech Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Why is aTyr Pharma stock gaining today?
- Investing.com
- Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Life Tech Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Life Tech Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
4 Buy
5 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2.857
(+411.12% Upside)
aTyr Pharma Inc SWOT Analysis
Analyst Outlook | Price targets range from $11 to $35, reflecting optimism about aTyr's novel approach and upcoming clinical milestones in 2025 |
Pipeline Progress | Delve into aTyr's expanding portfolio, including ATYR2810 for brain cancer and Efzofitimod's potential in systemic sclerosis-related interstitial lung disease |
Market Opportunity | Explore the potential $424 million market for Efzofitimod in pulmonary sarcoidosis, with analysts projecting significant growth in multiple indications |
Innovative Biologics | aTyr Pharma's lead candidate Efzofitimod, derived from tRNA synthetase biology, targets inflammation in pulmonary sarcoidosis and other fibrotic diseases |
aTyr Pharma Inc Earnings Call Summary for Q4/2024
- aTyr Pharma Q4 2024 EPS of -$0.18 beat expectations of -$0.23, with $75.1M cash on hand and $200K revenue from collaborations
- Phase III EFSOFIT study enrollment completed; top-line data expected Q3 2024 for lead candidate Esofitamod in pulmonary sarcoidosis
- Stock rose 12.39% in regular trading but fell 9.77% after hours; analysts maintain strong buy consensus with $9-$35 price targets
- R&D expenses of $54.4M reflect ongoing investment in therapeutic candidates; company exploring additional indications and pipeline development
- CEO Sanjay Shukla emphasized scientific advancements and potential impact across medical fields; EFSOFIT study maintains 90% statistical power
Last Updated: 03/13/2025, 06:17 PM
Read Full TranscriptEarnings
Latest Release
Aug 10, 2026
EPS / Forecast
-0.11 / -0.12
Revenue / Forecast
189.56M / --
Compare ATYR to Peers and Sector
Metrics to compare | ATYR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATYRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −2.5x | −0.4x | |
PEG Ratio | −0.04 | 0.01 | 0.00 | |
Price / Book | 1.1x | 3.2x | 2.6x | |
Price / LTM Sales | 288.6x | 25.8x | 3.1x | |
Upside (Analyst Target) | - | 65.8% | 48.4% | |
Fair Value Upside | Unlock | 12.8% | 6.5% | Unlock |
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the aTyr Pharma (ATYR) Stock Price Today?
The aTyr Pharma stock price today is 0.559 USD.
What Stock Exchange Does aTyr Pharma Trade On?
aTyr Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for aTyr Pharma?
The stock symbol for aTyr Pharma is "ATYR."
What Is the aTyr Pharma Market Cap?
As of today, aTyr Pharma market cap is 55.320M USD.
What Is aTyr Pharma's Earnings Per Share (TTM)?
The aTyr Pharma EPS (TTM) is -0.621.
When Is the Next aTyr Pharma Earnings Date?
aTyr Pharma will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is ATYR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has aTyr Pharma Stock Split?
aTyr Pharma has split 1 times.
How Many Employees Does aTyr Pharma Have?
aTyr Pharma has 59 employees.
What is the current trading status of aTyr Pharma (ATYR)?
As of Aug 14, 2026, aTyr Pharma (ATYR) is trading at a price of 0.559 USD, with a previous close of 0.553 USD. The stock has fluctuated within a day range of 0.550 USD to 0.587 USD, while its 52-week range spans from 0.395 USD to 6.500 USD.
What Is aTyr Pharma (ATYR) Price Target According to Analysts?
The average 12-month price target for aTyr Pharma is 2.857 USD, with a high estimate of 7 USD and a low estimate of 1 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +411.12% Upside potential.
What Is the ATYR Premarket Price?
ATYR's last pre-market stock price is 0.571 USD. The pre-market share volume is 8,220.000, and the stock has decreased by 0.018, or 3.250%.
What Is the ATYR After Hours Price?
ATYR's last after hours stock price is 0.525 USD, the stock has decreased by -0.034, or -6.080%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.